Price movement over the last 24 hours
Global X FTSE Southeast Asia ETF vs FMC Corp — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while FMC Corp trades at $10.93 (market cap $1.37B). The key difference: FMC Corp pays a 2.93% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, FMC Corp nearer its low. Which is the better fit depends on your goals.
| ASEA | FMC | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $20.65 | $43.90 |
52-Week Low | $16.31 | $10.80 |
Market Cap | — | $1.37B |
Enterprise Value | — | $5.51B |
Dividend Yield | — | 2.93% |
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
FMC Corporation (FMC) trades at $10.91, showing minimal daily movement with a 0.18% gain. The stock faces significant fundamental challenges, including a net loss of -$2.24 billion in 2025 and negative profit margins, though recent strategic moves like a $400 million investment from Tessenderlo Group and asset sales aim to reduce debt. Technical indicators are bearish, with the stock trading near key support levels. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings but a consensus price target of $17.00 suggesting substantial upside potential from current levels.
The outlook for FMC hinges on successful debt reduction and the commercial success of new products like rimisoxafen. While the current valuation metrics (P/S: 0.4, P/B: 0.75) appear attractive, the deeply negative profitability and high debt load present significant risks. The potential for a operational turnaround exists, but investors should weigh the high risk of continued losses against the possibility of a recovery driven by new technology and improved financial health.
Trailing returns across standard periods
Latest headlines on both assets
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →